Leading allergy researchers present data from a new, large, ‘real-world evidence’ study of allergy immunotherapy at EAACI Annual Congress in...
New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress...
Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAEZUG, Switzerland, July 10,...
- 95% complete response rate after single dose of CDX-0159 -- Rapid, profound and durable responses offer patients opportunity for...